In patients with advanced hepatocellular carcinoma, after atezolizumab-bevacizumab failure, second-line hepatic arterial infusion chemotherapy yielded higher response rates and longer progression-free survival than tyrosine kinase inhibitors.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: